Clinical Trials Logo

Sleep Disturbance clinical trials

View clinical trials related to Sleep Disturbance.

Filter by:

NCT ID: NCT05253417 Completed - Insomnia Clinical Trials

The CANabidiol Use for RElief of Short Term Insomnia

CANREST
Start date: May 1, 2022
Phase: Phase 2
Study type: Interventional

This study aims to investigate the effect of 50 mg and 100 mg per day oral CBD product versus a placebo over 8 weeks on insomnia severity in adults aged 18-65 years old with insomnia symptoms.

NCT ID: NCT05252598 Withdrawn - Anxiety Clinical Trials

Mood and Cognitive Effects of Psilocybin in Healthy Participants

MELO
Start date: January 2023
Phase: Early Phase 1
Study type: Interventional

This study is seeking to find the optimal microdose or low dose of psilocybin (magic mushrooms) that provides general enhancements to mood, memory, sleep, and other measures of general well-being without any hallucinogenic effects.

NCT ID: NCT05236504 Recruiting - Sleep Disturbance Clinical Trials

Effects of a Novel Supplement on Sleep, Metabolism, Body Composition and Performance

4BETTSLEEP
Start date: November 28, 2021
Phase: N/A
Study type: Interventional

This study aimed to investigate the effects of a novel dietary supplement, consisting of melatonin and magnesium in a pod (coffee machine capsule) format, on sleep quality, stress, mood, sleepiness, biological rhythms, metabolism, body composition and performance, in individuals with sleep disturbances according with the Pittsburgh Sleep Quality Index. A randomized, double-blind, crossover trial will be conducted to compare the effects of the melatonin and magnesium-containing supplement against a placebo. The protocol comprises 4 weeks of supplementation with an experimental or placebo condition, with a week-long washout period. Biochemical markers of sleep and stress, actigraphy for sleep patterns and sleep hygiene, resting metabolic rate, food and fluid intake, body composition, and handgrip strength measures will be evaluated at baseline and 4 weeks post each randomly assigned intervention. The working hypothesis is that this innovative supplement will provide greater objective and subjective improvements regarding sleep patterns and quality, overall mood, biochemical markers of stress, resting metabolic rate, energy intake, body composition and strength, than the placebo comparator, due to the synergic effects of melatonin and magnesium.

NCT ID: NCT05206734 Completed - Schizophrenia Clinical Trials

Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health

Start date: January 5, 2022
Phase:
Study type: Observational

This study is a large population-based analysis in the United Kingdom (UK) using routine primary care data to investigate the risk of mental health conditions in children, adolescents and young adults with Inflammatory Bowel Disease, compared to those without Inflammatory Bowel Disease. The study will also compare the impacts on quality-of-life outcomes and use of healthcare services between people with Inflammatory Bowel Disease with and without mental health conditions.

NCT ID: NCT05182814 Completed - Sleep Disturbance Clinical Trials

Efficacy Testing of Collagen Drink on Skin Beauty and Sleep Aid

Start date: November 10, 2021
Phase: N/A
Study type: Interventional

To assess Collagen Drink on skin condition and sleep quality improvement

NCT ID: NCT05120310 Completed - Sleep Disturbance Clinical Trials

Effects of Health and Wellness App on Employee Productivity

Start date: August 6, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to test the effects of using the Calm app + coaching concierge (one 20-min session) and/or Calm Coaching for sleep program on sleep, mental health, and work productivity outcomes in employees. Employees (N=5,000) will be randomized into one of two groups for 8-weeks.

NCT ID: NCT05097651 Withdrawn - Sleep Disturbance Clinical Trials

CBD for Sleep in People With HIV

Start date: April 1, 2021
Phase: Phase 2
Study type: Interventional

This study will obtain preliminary information about whether, and at what dose, cannabidiol (CBD) may help with insomnia in people living with human immunodeficiency virus (HIV). The study will be a 5-week randomized, double-blind placebo-controlled phase II trial using daily oral CBD doses between 50mg and 600mg. Sleep problems will be measured using a wrist-worn device and by self-report. Performance on tests of thinking skills will be compared before and after CBD/placebo treatment. Positive study results will provide support for the use of CBD as a potential treatment for insomnia.

NCT ID: NCT05093465 Completed - Sleep Disturbance Clinical Trials

A Comparison of Two Behavioral Sleep Interventions Among College Students (ProjectTECH)

Start date: September 25, 2018
Phase: N/A
Study type: Interventional

The study was a randomized controlled trial designed to examine whether augmenting traditional sleep hygiene and stimulus control procedures with technology use reduction stimulus control procedures would produce better sleep and technology usage outcomes.

NCT ID: NCT05044975 Recruiting - Sleep Disturbance Clinical Trials

Improving Sleep in Gynecologic Cancer Survivors

Start date: October 11, 2021
Phase: N/A
Study type: Interventional

This purpose of this study is to learn about how to provide treatment to gynecologic cancer survivors who have difficulty sleeping.

NCT ID: NCT05043038 Enrolling by invitation - Fatigue Clinical Trials

Effect of Night Float Call on Sleep and Activity Patterns Among Anesthesia Residents

Start date: August 1, 2019
Phase:
Study type: Observational

With increasing awareness about physician fatigue and its effect on patient safety, residency programs are increasingly transitioning to a night float call system. In other industries, multiple night shifts in a row can cause a disruption in the circadian rhythm, sleep debt, shift work disorder, that is related to chronic medical conditions such as obesity and cardiovascular disease. We will evaluate the effect of different call structures on resident activity, sleep and self reported measures of wellness using a commercially available Fitbit device.